A hybrid application sits between a generic and a full dossier. It relies on the reference product for part of the evidence and on your own data for the difference, and getting that boundary right decides how many studies you will need.
When the hybrid route applies
Article 10(3) of Directive 2001/83/EC applies where the product does not fit the strict definition of a generic medicinal product, or where bioavailability studies cannot demonstrate bioequivalence, or where there are changes in the active substance, therapeutic indications, strength, pharmaceutical form or route of administration compared with the reference product.
In those cases the results of appropriate pre-clinical tests or clinical trials must be provided for the differences, while the rest of the evidence can still rely on the reference product.
Typical hybrid scenarios
- A different salt, ester or derivative of the reference active substance, where safety or efficacy may differ.
- A new strength or pharmaceutical form, such as a modified-release version of an immediate-release reference.
- A different route of administration, for example moving between topical and systemic exposure.
- Products where equivalence cannot be shown by standard bioequivalence studies, such as certain locally acting products.
Defining the data package
The central question is: what is different, and what does the difference do to the benefit-risk profile? Each difference should be mapped to a data requirement, whether a bridging pharmacokinetic study, a limited non-clinical study or a clinical efficacy and safety study. Scientific advice from a national authority or the EMA is often worth seeking before investing in studies.
Reference product choice matters. It must be authorised in the EU and the reference product relationship, including the data-exclusivity periods that have to expire before the application can be submitted or approved, must be checked early.
Presenting the dossier
Make the reliance explicit in the overviews: state what is taken from the reference product, what is new, and why the new data are sufficient. Reviewers should not have to infer the logic. Module 3 must meet full quality standards regardless of the legal basis.
Planning the reference product and exclusivity
Before filing, confirm which product is the reference, in which member states it was authorised, and when the relevant data-exclusivity and market-protection periods expire. For decentralised and mutual recognition procedures, the reference product choice affects every concerned member state, so check availability and the status of the product in each. A mistake here can invalidate the legal basis and force a re-filing, which is far more costly than a few extra days of checking. Decide on the legal basis first, and design the development programme around it rather than the other way round.
How PQRA helps
PQRA can assess whether your product is a generic, a hybrid or needs a full application, define the minimum credible data package, prepare the scientific advice request and write the dossier so that reliance on the reference product is transparent to assessors.
Contact PQRA to discuss your dossier and procedure.


No responses yet